Ignite Creation Date:
2024-05-06 @ 4:06 PM
Last Modification Date:
2024-10-26 @ 2:03 PM
Study NCT ID:
NCT04873492
Status:
RECRUITING
Last Update Posted:
2023-01-30
First Post:
2021-04-30
Brief Title:
From Genetics to Transcriptomics to Unravel the Mechanisms Behind a Poor Outcome in Multiple Sclerosis
Sponsor:
Nantes University Hospital
Organization:
Nantes University Hospital
Study Overview
Official Title:
From Genetics to Transcriptomics to Unravel the Mechanisms Behind a Poor Outcome in Multiple Sclerosis
Status:
RECRUITING
Status Verified Date:
2023-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
OUTCOMS
Brief Summary:
MS is a heterogeneous disease either in its response to treatment or clinical manifestation Indeed the natural history of MS is varying from a benign condition to a devastating and rapidly incapacitating disease Clinical heterogeneity could also be cellular and or molecular The aim is to identify from OMIC analyses at the early stage of the disease differentially expressed molecules and or cell subpopulations derived from CD8 T lymphocytes and or CD4 T lymphocytes and or B lymphocytes and monocytes from patients with aggressive versus non-aggressive compared to a cohort of healthy controls
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None